Additional data for Aurinia Pharmaceuticals Inc.'s voclosporin in the Phase IIb AURA-LV clinical trial show a much improved complete response rate for patients with lupus nephritis relative to the comparator arm of the trial after 48 weeks, boosting the company's stock and expectations for a positive result in Phase III.
Previously reported 24-week data also showed a significant response for lupus nephritis (LN) patients treated with voclosporin, but the 48-week...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)